[Intraarterial neoadjuvant chemotherapy for extremity osteosarcoma].

Area of Science:

• Orthopedic Oncology
• Medical Oncology
• Cancer Chemotherapy

Context:

• Osteosarcoma is a primary bone malignancy predominantly affecting children and young adults.
• Extremity osteosarcoma presents unique challenges for surgical resection and limb preservation.
• Neoadjuvant chemotherapy aims to reduce tumor burden and improve surgical margins prior to definitive treatment.

Purpose:

• To evaluate the efficacy of standard versus nonstandard intraarterial neoadjuvant chemotherapy in patients with stage IIB extremity osteosarcoma.
• To compare outcomes including limb preservation rates, overall survival, disease-free survival, and recurrence rates.

Summary:

• A study of 111 patients with stage IIB extremity osteosarcoma compared standard (3-6 cycles) and nonstandard (2 cycles) intraarterial neoadjuvant chemotherapy regimens.
• The standard chemotherapy group demonstrated significantly higher rates of extremity preservation surgery (89.53% vs. 37.5%).
• Kaplan-Meier analysis revealed superior 3-year overall survival (80.0% vs. 38.9%) and disease-free survival (79.5% vs. 30.1%) in the standard group, with lower distant metastatic and local recurrence rates.

Impact:

• Standardized intraarterial neoadjuvant chemotherapy protocols are crucial for optimizing treatment outcomes in extremity osteosarcoma.
• This regimen enhances limb salvage rates and improves long-term survival for patients with this aggressive bone cancer.
• Findings support the adoption of standard intraarterial chemotherapy protocols in clinical practice for stage IIB extremity osteosarcoma.